


Company Profile

Boehringer Ingelheim: Value through Innovation

Improving the health and lives of humans and animals is the goal of the research-driven biopharmaceutical company Boehringer Ingelheim. The focus is on diseases in areas with a high unmet medical need. The company therefore concentrates on developing innovative therapies that can improve and extend lives. In Animal Health, Boehringer Ingelheim is one of the world's leading providers of vaccines, therapeutics and preventative care offering that protect animals from disease and pain.

Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Our aim is to transform the lives of patients – across generations. This goal inspires all of our over 53,000 employees who create value through innovation. In 2022, Boehringer Ingelheim achieved net sales of 24.1 billion euros.



Generating 77 percent of total net sales, Human Pharma is the largest business area of Boehringer Ingelheim. The company's diabetes medications, which Boehringer Ingelheim markets together with Eli Lilly and Company, have driven growth. JARDIANCE® was the best-selling product in 2022, with net sales of 5.8 billion euros. OFEV®, which is used for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs), was the second-strongest product with net sales of around 3.2 billion euros. The diabetes medications TRAJENTA® and JENTADUETO® as well as the respiratory medicine SPIRIVA® accounted for more than 3.0 billion euros.

The Boehringer Ingelheim Animal Health business, a global leader in animal health, delivered net sales of around 4.6 billion euros in 2022, representing 19 percent of total net sales. The company's integrated product portfolio features more than 200 products for dogs, cats, horses, pigs, cattle and poultry. The parasiticides NEXGARD® and FRONTLINE® for dogs and cats, HEARTGARD® for dogs as well as the



Contact: Boehringer Ingelheim Corporate Affairs

Harro Ten Wolde 55216 Ingelheim, Germany Phone: +49 (0) 6132 77 181352 Email: press@boehringeringelheim.com









swine vaccines INGELVAC CIRCOFLEX*/ FLEXCOMBO* are some of the best-known brands.

In 2022, the Biopharmaceutical Contract Manufacturing business generated net sales of 1.0 billion euros, which represents four per cent of total revenues. Boehringer Ingelheim is a world-leading contract manufacturer of biopharmaceuticals, using cell cultures and microorganisms at its facilities in Germany (Biberach), Austria (Vienna), USA (Fremont) and China (Shanghai). With the opening of the new biopharmaceutical production facility (Large Scale Cell Culture) in Vienna, Austria, in October 2021, the company completed the single largest capital investment of more than 700 million euros in its history.

Overall, Boehringer Ingelheim generated sales in the regions Americas (48 percent of total net sales), Europe (31 percent) and Australia / Asia / Africa (21 percent) in 2022.

Focus on research and development (R&D)

In the field of human pharma, Boehringer Ingelheim is active in the research areas of cardiometabolic diseases, oncology, respiratory diseases, immunology, diseases of the central nervous system and retinal health. The company spent some 5.0 billion euros on research and development worldwide in 2022, with R&D expenses on human pharma alone accounting for 24.8 percent of net sales generated in this area. The global research network for human pharmaceuticals includes facilities in Germany (Biberach and Ochsenhausen), the USA (Ridgefield), Austria (Vienna and Innsbruck), Japan (Kobe) and Switzerland (Basel and Geneva).

Global research network for Animal Health

Boehringer Ingelheim has also an established global innovation network for Animal Health with 17 R&D sites around the world. The focus is on innovative vaccines and parasiticides for the protection of livestock and companion animals, as well as therapeutics for the treatment of chronic diseases and other debilitating conditions.

Additional information can be found on:

<u>www.boehringer-ingelheim.com</u> and in the 2022 Annual Report: <u>annualreport.boehringer-ingelheim.com/2022/</u>